This laboratory is a specialized facility at the UPCI dedicated to the state-of-the-art evaluation of immune responses prior to, during and after biotherapy in patients with cancer. It also generates cellular products for human therapy. In its role as Core B for this PPG, the IMCPL will assume responsibility for supporting the vaccine-based clinical trials planned by Projects 2 and 3. Core B, functioning as a GMP facility, will culture and characterize dendritic cells (DC) for patient therapy, prepare vaccines by pulsing these DC with peptides or tumor cells and by co-incubating DC with tumor cells to produce DC-tumor hybrids. Core B will be responsible for quality and sterility of the DC-based vaccines. It will also procure, process and distribute to investigators all tissue or body fluids harvested in the course of the clinical protocols. Core B will be prepared to assist the PPG investigators in implementing assays necessary for evaluation of immunologic responses to the administered vaccines. The Core will ensure that all cellular products it generates and samples it collects are accompanied by appropriate documentation that will permit linking laboratory analyses with clinical results. This Core laboratory will be entirely dedicated to the support of the clinical trials proposed in the PPG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA073743-09
Application #
7478057
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
9
Fiscal Year
2007
Total Cost
$151,952
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Macatangay, Bernard J C; Riddler, Sharon A; Wheeler, Nicole D et al. (2016) Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis 213:1400-9
Lohmueller, Jason J; Sato, Shuji; Popova, Lana et al. (2016) Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep 6:31740
Keyel, Peter A; Roth, Robyn; Yokoyama, Wayne M et al. (2013) Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation. Toxins (Basel) 5:1105-18
Zhang, Lixin; Vlad, Anda; Milcarek, Christine et al. (2013) Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62:423-35
Sun, Chengqun; Heid, Michelle E; Keyel, Peter A et al. (2013) The second transmembrane domain of P2X7 contributes to dilated pore formation. PLoS One 8:e61886
Kimura, Takashi; McKolanis, John R; Dzubinski, Lynda A et al. (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6:18-26
Miskov-Zivanov, Natasa; Turner, Michael S; Kane, Lawrence P et al. (2013) The duration of T cell stimulation is a critical determinant of cell fate and plasticity. Sci Signal 6:ra97
Keyel, Peter A; Tkacheva, Olga A; Larregina, Adriana T et al. (2012) Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol 189:4621-9
Cramer, Daniel W; Finn, Olivera J (2011) Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 23:265-71
Morel, Penelope A; Turner, Michael S (2011) Dendritic cells and the maintenance of self-tolerance. Immunol Res 50:124-9

Showing the most recent 10 out of 90 publications